Cargando…
Ceftriaxone-Associated Severe Acute Hepatitis
Drug-induced liver injury (DILI) is a common entity. Ceftriaxone is a well-tolerated parenteral antibiotic widely used for various bacterial infections. We report a patient who developed severe acute hepatitis following a single dose of 2 g ceftriaxone within one day. Apart from a fever of 101.9 F,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110998/ https://www.ncbi.nlm.nih.gov/pubmed/37082506 http://dx.doi.org/10.7759/cureus.36341 |
_version_ | 1785027368577925120 |
---|---|
author | Asif, Muhammad Khan, Wahab J Aslam, Sadia Nadeem, Ifrah Singal, Ashwani K |
author_facet | Asif, Muhammad Khan, Wahab J Aslam, Sadia Nadeem, Ifrah Singal, Ashwani K |
author_sort | Asif, Muhammad |
collection | PubMed |
description | Drug-induced liver injury (DILI) is a common entity. Ceftriaxone is a well-tolerated parenteral antibiotic widely used for various bacterial infections. We report a patient who developed severe acute hepatitis following a single dose of 2 g ceftriaxone within one day. Apart from a fever of 101.9 F, no other insult was noted to explain his severe hepatocellular injury around the time of presentation. On stopping further ceftriaxone, his symptoms resolved, and liver enzymes normalized within a week. His Roussel Uclaf Causality Assessment Method (RUCAM) score was 6 which suggested DILI be a probable cause of his acute hepatitis. Further surveillance at a larger scale is needed to support evidence for this rare side effect. |
format | Online Article Text |
id | pubmed-10110998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-101109982023-04-19 Ceftriaxone-Associated Severe Acute Hepatitis Asif, Muhammad Khan, Wahab J Aslam, Sadia Nadeem, Ifrah Singal, Ashwani K Cureus Internal Medicine Drug-induced liver injury (DILI) is a common entity. Ceftriaxone is a well-tolerated parenteral antibiotic widely used for various bacterial infections. We report a patient who developed severe acute hepatitis following a single dose of 2 g ceftriaxone within one day. Apart from a fever of 101.9 F, no other insult was noted to explain his severe hepatocellular injury around the time of presentation. On stopping further ceftriaxone, his symptoms resolved, and liver enzymes normalized within a week. His Roussel Uclaf Causality Assessment Method (RUCAM) score was 6 which suggested DILI be a probable cause of his acute hepatitis. Further surveillance at a larger scale is needed to support evidence for this rare side effect. Cureus 2023-03-18 /pmc/articles/PMC10110998/ /pubmed/37082506 http://dx.doi.org/10.7759/cureus.36341 Text en Copyright © 2023, Asif et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Asif, Muhammad Khan, Wahab J Aslam, Sadia Nadeem, Ifrah Singal, Ashwani K Ceftriaxone-Associated Severe Acute Hepatitis |
title | Ceftriaxone-Associated Severe Acute Hepatitis |
title_full | Ceftriaxone-Associated Severe Acute Hepatitis |
title_fullStr | Ceftriaxone-Associated Severe Acute Hepatitis |
title_full_unstemmed | Ceftriaxone-Associated Severe Acute Hepatitis |
title_short | Ceftriaxone-Associated Severe Acute Hepatitis |
title_sort | ceftriaxone-associated severe acute hepatitis |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110998/ https://www.ncbi.nlm.nih.gov/pubmed/37082506 http://dx.doi.org/10.7759/cureus.36341 |
work_keys_str_mv | AT asifmuhammad ceftriaxoneassociatedsevereacutehepatitis AT khanwahabj ceftriaxoneassociatedsevereacutehepatitis AT aslamsadia ceftriaxoneassociatedsevereacutehepatitis AT nadeemifrah ceftriaxoneassociatedsevereacutehepatitis AT singalashwanik ceftriaxoneassociatedsevereacutehepatitis |